INTRODUCTION
The worldwide prevalence of diabetes was estimated at 366 million in 2011 (8.3% of the population), and is predicted to rise to 552 million (9.9%) by 2030 [1] ; type 2 diabetes accounts for approximately 95% of these cases [2] . Treatment in patients with type 2 diabetes varies with age; for example, elderly patients may be more likely than younger patients to have comorbidities and need polypharmacy, which, in the case of some drugs, may disrupt glycemic control, reduce quality of life, and increase the risk of severe hypoglycemia [3] [4] [5] [6] .
Furthermore, elderly patients may be unable to adequately self-monitor blood glucose levels due to poor dexterity, and cognitive and visual impairments [7] . The differences between patient age-groups emphasize the need for individualized care in these different groups. With their more favorable clinical profiles (lower risk of hypoglycemia, flexible dosing, improved convenience, and greater treatment satisfaction) compared with human insulin [8, 9] , insulin analogs may be a better choice for starting or optimizing insulin therapy for most patients, including the elderly [3] .
Insulin aspart (NovoRapid Ò ; Novo Nordisk A/S, Bagsvaerd, Denmark) is a rapid-acting insulin analog that can be administered immediately before or after a meal [10] , and a large body of evidence supports the clinical utility of insulin aspart when administered as part of a basal-bolus regimen [11] [12] [13] [14] [15] [16] [17] . In addition to the data from randomized clinical trials, observational studies have demonstrated that basal-bolus regimens are effective in everyday practice in type 1 and type 2 diabetes [18] [19] [20] . There is a lack of specific clinical studies in different age-groups to elucidate the risks and benefits of existing treatments in older compared with younger patients, and therefore, large observational studies can be invaluable for providing data from this cohort of patients. A 1 chieve was an international noninterventional study that was conducted to examine the safety and effectiveness of initiating or switching to insulin analogs (alone/in combination with other anti-diabetes medication) as part of routine clinical care among patients with type 2 diabetes [18] . In this sub-group analysis of the A 1 chieve study, we aimed to investigate the safety and effectiveness of insulin aspart administered at mealtime(s) as required, together with basal insulin (insulin detemir, neutral protamine
Hagedorn or insulin glargine) with or without oral glucose-lowering drugs (OGLDs) in three age-groups (B40, [40-65 and [65 years of age) with type 2 diabetes.
MATERIALS AND METHODS

All local requirements for Health Authorities or
Ethics Committee approvals were obtained, if applicable. In every country, participants signed informed consent forms and were free to withdraw from the study at any time. The study was conducted in accordance with the Declaration of Helsinki of 1964, as revised in 2008 [21] and the Guidelines for Good Pharmacoepidemiology Practice [22] .
Study Design
This was a sub-analysis of a 24-week, most recent during the preceding 4 weeks), FPG (pre-breakfast), and post-prandial plasma glucose (PPG; 90 to 120 min after the beginning of breakfast)], body weight, and health-related quality of life (HRQoL). HRQoL was measured by self-report at baseline and after 24 weeks using the EQ-5D questionnaire [23] , which evaluates five domains of patient health/ lifestyle (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).
Scores in these five domains were converted to a single utility value (UK VAS set), with '1.00' indicating 'full health' and '0.00' indicating the state 'deceased' [24, 25] .
Due to the observational nature of the study and lack of protocol enforcement to report all effectiveness outcomes, results are reported here as per available reports.
Statistical Analyses
Analyses were performed in all patients with a baseline visit and who were treated with insulin aspart as part of a basal-bolus regimen at baseline. For those patients who withdrew from the study, data collected until the date of withdrawal was used for analysis. Sub-group analyses were conducted according to age (B40, [40-65 and [65 years), and pre-study insulin experience (insulin-experienced and insulin-naive).
The sample size (full cohort) was based on the number of people (20,000) exposed for 6 months required to confirm at 95% confidence a frequency of any one adverse drug reaction of C15 events/100,000 person-years. This would detect a rate of major hypoglycemia as reported in any published clinical trial.
Changes from baseline in efficacy measures were evaluated using Student's paired t test. For hypoglycemia, the percentage of patients reporting at least one event was analyzed using McNemar's test. All statistical analyses were two-sided, using a pre-specified 5% significance level, and were performed by Novo Nordisk using SAS Ò Version 9.1.3 (SAS Ò Institute Inc., Cary, NC, USA).
RESULTS
Study Participants
Data for 4,032 people (6% of the total A 1 chieve Mean (SD) bolus insulin dose increased slightly from baseline to 24 weeks in all age- Due to the observational nature of the study, data were not collected or not recorded for some patients BMI body-mass index a n = 2,799, n = 659 for the [40-65 and [65 years age-groups, respectively b n = 549, n = 2,700, n = 635 for the B40, [40-65 and [65 years age-groups, respectively c n = 517, n = 2,621, n = 612 for the B40, [40-65 and [65 years age-groups, respectively d n = 552, n = 2,785, n = 657 for the B40 Metformin and/or sulfonylureas were the predominant OGLDs in all age-groups at study initiation and after 24 weeks of treatment with insulin aspart; [70% of patients in all agegroups were prescribed metformin after 24 weeks.
SADRs
Of the 4,032 people with type 2 diabetes who received insulin aspart as part of a basal-bolus regimen, there were 14 reports of SADRs: five hypoglycemia episodes in the B40 years Fig. 1 Oral glucose-lowering drug use among patients starting or switching to a basal-bolus insulin regimen with insulin aspart in the A 1 chieve study. n = 264 pre-study, n = 194 at baseline and n = 204 at 24 weeks in B40 years age-group. n = 2,062 pre-study, n = 1,479 at baseline and n = 1,467 at 24 weeks in[40-65 years age-group. n = 440 pre-study and n = 270 at baseline and 24 weeks in[65 years age-group. OGLD oral glucose-lowering drug age-group; five in the [40-65 years age-group, including two hypoglycemia episodes, one report of diabetic ketoacidosis, one report of a fall, and one report of a pelvic fracture; and four in the [65 years age-group, including two hypoglycemia episodes, one report of inadequate diabetes control, and one episode of hypoglycemia unconsciousness. All SADRs occurred in insulin-experienced patients.
Eleven of these events were probably related to treatment (with good reasons and sufficient documentation to assume a causal relationship) and three were possibly related (a causal relationship was conceivable and could not be dismissed).
Hypoglycemia
In each age-group (in the entire cohort), there was a significant reduction from baseline in overall hypoglycemia, major hypoglycemia, and nocturnal hypoglycemia after 24 weeks of treatment with insulin aspart as part of a basalbolus regimen (Table 2 ). There were no reports of major hypoglycemia at 24 weeks in the [40-65 years age-group and [65 years agegroup ( Table 2) . Rates of hypoglycemia, major hypoglycemia and nocturnal hypoglycemia were numerically higher at baseline among insulin-experienced than insulin-naive patients ( Table 2) . Rates of hypoglycemia and nocturnal hypoglycemia were significantly reduced in all three agegroups of insulin-experienced patients after 24 weeks of treatment with insulin aspart as part of a basal-bolus regimen ( Table 2 ). However, rates of nocturnal hypoglycemia did not significantly increase with insulin aspart treatment in insulin-naive patients of any agegroup, and there were no reports of major hypoglycemia at 24 weeks ( Table 2) .
The proportion of patients taking sulfonylureas who reported hypoglycemia events at baseline was 9.6% (n = 115), 11.7%
(n = 1,109), and 15.1% (n = 232) in the B40 years age-group, [40-65 years age-group, and [65 years age-group, respectively. At 24 weeks, there was no significant change from baseline in the proportion of patients reporting hypoglycemia events: 3.6% (n = 28), 7.1% (n = 254) and 4.7% (n = 43), respectively.
Glucose Control
Baseline HbA 1c levels were high in all agegroups in insulin-naive and insulinexperienced patients (Fig. 2) (Fig. 2) .
The proportion of patients (insulinnaive plus insulin-experienced) with HbA 1c \7.0% at baseline was similar between agegroups at baseline (3.5-6.9%) and at 24 weeks (32.8-35.9%). A greater proportion of patients appeared to achieve HbA 1c \7.0% following 24 weeks of treatment with insulin aspart as part of a basal-bolus regimen than at baseline (Table 3 ). In the [65 years age-group, 12.0% and 14.3% of patients had baseline HbA 1c \7.5% in the insulin-naive and insulinexperienced cohorts, respectively. Following 24 weeks of treatment with insulin aspart as part of a basal-bolus regimen, 63.0% and 55.0% patients aged [65 years achieved HbA 1c \7.5%.
Baseline FPG was high in all age-groups in insulin-naive and insulin-experienced patients, and significantly improved in all age-groups after 24 weeks treatment with insulin aspart as part of a basal-bolus regimen (Table 3) . Baseline FPG values were higher in insulin-naive than insulin-experienced patients, and improvements were numerically greater in insulin-naive patients than in insulinexperienced patients (Table 3) . Furthermore, baseline FPG was slightly higher at younger ages, and the reductions after 24 weeks were * p\0.05 vs. baseline; ** p\0.01 vs. baseline; *** p\0.001 vs. baseline a n for each cohort same as for hypoglycemia (overall) data correspondingly greater in the younger agegroup (Table 3) . Likewise, baseline postbreakfast PPG was high in all age-groups and higher in insulin-naive than insulinexperienced patients (Table 3) . After 24 weeks treatment with insulin aspart as part of a basalbolus regimen, statistically significant improvements in PPG were observed in all sub-groups and these were greater in insulinnaive groups than insulin-experienced groups (Table 3) .
Body Weight
Baseline body weight was higher in the [40-65 years age-group than the other two agegroups (Table 3) . Weight remained stable after 24 weeks treatment with insulin aspart as part of a basal-bolus regimen in the B40 and [65 years age-groups, but there was a significant weight loss in patients aged [40-65 years (Table 3 ). In insulin-experienced patients, there was a significant weight increase in the B40 years agegroup, a significant weight loss in the [40-65 years age-group, and no significant change in weight in the [65 years age-group (Table 3) . By contrast, weight remained stable after 24 weeks treatment with insulin aspart as part of a basal-bolus regimen in all age-groups in the insulin-naive cohort (Table 3) .
Health-Related Quality of Life
Statistically significant improvement in UK VAS scores after 24 weeks were observed in all agegroups except insulin-naive patients in the B40 years age-group (Table 3) . This younger age-group had considerably higher UK VAS scores (i.e., better HRQoL) at baseline than the older age-groups, regardless of previous therapy. Patients in the insulin-experienced B40 years age-group had particularly high rates of hypoglycemia, nocturnal hypoglycemia and major hypoglycemia at baseline. However, the proportion of patients reporting hypoglycemia episodes decreased on the basal-bolus regimen with insulin aspart in all age-groups, and great reassurance can be drawn from the very low rates of major hypoglycemia after 24 weeks.
DISCUSSION
Furthermore, sulfonylurea use did not appear to increase the rate of hypoglycemia in any agegroup; indeed improvements in hypoglycemia were achieved despite between 13.7% and Table 3 continued 17.3% of patients in all age-groups receiving sulfonylureas at 24 weeks. While guidelines recommend discontinuation of sulfonylureas on commencement of more complex insulin regimens (such as basal-bolus insulin regimens) in order to minimize the risk of hypoglycemia episodes, this does not always occur in practice [27] . The beneficial effect of insulin aspart as part of a basal-bolus regimen on hypoglycemia may therefore reflect the overall reduction in polypharmacy.
Elderly patients are at greater risk of hypoglycemia events than patients of a younger age [3] . This, together with the association of hypoglycemia with the use of basal-bolus therapy, may have raised concerns over the application of this regimen in elderly patients. However, the results from this study showed that elderly patients in both the entire cohort and the insulin-experienced cohort had lower rates of hypoglycemia following 24 weeks of a basal-bolus regimen with insulin aspart versus baseline. Indeed, the rate in the oldest age-group was similar to the younger agegroups after 24 weeks of treatment (in both insulin-experienced and insulin-naive populations). Consistent with earlier reports [5, 6] benefits in use of insulin analogs in less developed countries.
In conclusion, insulin aspart administered within a basal-bolus regimen as part of routine clinical practice had efficacy and good tolerability in all age-groups as either a starting insulin regimen, or when patients were switched from other regimens. The results also show that the use of insulin aspart as part of a basal-bolus regimen is effective and tolerable in elderly people with diabetes, although treatment should be individualized.
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